P2.15-A Panorama Retro: Real World Evaluation of Molecular Testing and Treatment Patterns for EGFR Mutations in Patients with Advanced or Metastatic NSCLC (D133FR00143)

Abstract

Background: The diagnosis and treatment of lung cancer is currently governed by the selection of patients based on oncogenic alterations that allow specific therapies to be offered. The gene (ALK) is present in 3 to 7% of patients with non-small cell lung cancer (NSCLC) and confers sensitivity to ALK inhibitors with better response rates and PFS than with chemotherapy. Method: We performed a descriptive review of the response profile in patients with NSCLC with positive ALK mutation and who received treatment with alectinib. Tomography patterns were described, as well as the response achieved with the treatment.